慢性乙型肝炎病毒核心抗体定量检测的临床诊断价值

StephenW

慢性乙型肝炎病毒核心抗体定量检测的临床诊断价值
苏习1 2 , 陈黄平3 , 朱子飞1 2 , 谢万英1 2 , 彭建桥1 2 , 马新平1 2 , 金文文1 2 , 魏石1 2 , 中华邓1 2 , 李存艳1 2
隶属关系
隶属关系

    1
    湖南省人民医院（湖南师范大学第一附属医院）检验科，长沙 410005
    2
    湖南省人民医院（湖南师范大学第一附属医院）临床转化医学研究所临床检验室，湖南长沙410005
    3
    邵阳大学医学检验部, 邵阳 422099

    PMID：34853582 PMCID：PMC8629653 DOI：10.1155/2021/3720571

免费 PMC 文章
抽象的

CHB病毒（HBV）核心抗体（HBcAb）在慢性HBV感染的四个阶段水平不同，可用于慢性HBV感染自然病程的鉴别诊断。为了解决这个问题，我们检查了多种血液生物标志物并评估了诊断慢性 HBV 感染不同阶段的功效。定量检测73例低复制期（LR ）、免疫耐受期（IT）46例、免疫清除期（IC）44例、HBeAg阴性肝炎（ENH）57例。通过受试者工作特征（ROC）曲线分析来分析这些血清蛋白水平的区分性能。我们的结果表明，IC 和 ENH 组的 HBcAb、ALT 和 AST 水平显着高于 LR 组和 IT 组（均 P ≤ 0.001）。 IC和IT组HBV DNA和HBsAg水平高于LR组和ENH组（P均≤0.001）。 Logistic 回归模型显示 HBcAb、HBsAg、HBV DNA、ALT 和 AST 分别为自变量，当它们结合时，它们为 CHB 的分期提供了较高的诊断准确性。综上所述，HBcAb定量是一个新的指标，可以反映肝脏是否处于HBV感染的免疫激活状态，与宿主肝脏的炎症状态有关。 HBcAb定量和其他指标的联合检测对IC和ENH的分期显示出有希望的效率，可以辅助CHB的诊断和治疗。

版权所有 © 2021 Xi Su et al.

StephenW

Clinical Diagnostic Value of Quantitative Hepatitis B Virus Core Antibody Test in Chronic Viral Hepatitis B
Xi Su  1   2 , Huangping Chen  3 , Zifei Zhu  1   2 , Wanying Xie  1   2 , Jianqiao Peng  1   2 , Xinping Ma  1   2 , Wenwen Jin  1   2 , Wei Shi  1   2 , Zhonghua Deng  1   2 , Cunyan Li  1   2
Affiliations
Affiliations

    1
    Department of Laboratory Medicine, Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Changsha 410005, China.
    2
    Research Office of Clinical Laboratory, Clinical Translational Medicine Research Institute of Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Changsha 410005, China.
    3
    Department of Medical Laboratory, Shaoyang University, Shaoyang 422099, China.

    PMID: 34853582 PMCID: PMC8629653 DOI: 10.1155/2021/3720571

Free PMC article
Abstract

The level of CHB virus (HBV) core antibody (HBcAb) is different in four stages of chronic HBV infection and may be used for differential diagnosis of the natural history of chronic HBV infection. To address this question, we examined multiple blood biomarkers and assessed the efficacy to diagnose different stages of chronic HBV infection. The quantitative detection of HBcAb, hepatitis B surface antigen (HBsAg), HBV DNA, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count (PLT) were determined in the serum of 73 cases of low-replicative phase (LR), 46 cases of immune-tolerant phase (IT), 44 cases of immune clearance phase (IC), and 57 cases of HBeAg-negative hepatitis (ENH). Differentiating performance of these serum protein levels was analyzed by receiver operating characteristic (ROC) curve analysis. Our results showed that the levels of HBcAb, ALT, and AST levels were significantly higher in IC and ENH than those in LR and IT (both P ≤ 0.001). The levels of HBV DNA and HBsAg were higher in IC and IT than those in LR and ENH (both P ≤ 0.001). Logistic regression models showed that HBcAb, HBsAg, HBV DNA, ALT, and AST were the independent variables, respectively, and when combined, they provided high diagnostic accuracy for the staging of CHB. To sum up, HBcAb quantification is a new index, which can reflect whether the liver is in the immune activation state of HBV infection, and is related to the inflammatory state of the host liver. The combined detection of HBcAb quantification and other indicators has showed promising efficiency for staging of IC and ENH and can assist the diagnosis and treatment of CHB.

Copyright © 2021 Xi Su et al.

StephenW

https://www.hindawi.com/journals/bca/2021/3720571/